视网膜疾病治疗市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测，按类型、剂型、分销渠道、地区和竞争细分

由于视网膜疾病患病率不断增加、人口老龄化、医疗保健技术的进步以及医疗保健支出的增加等，预计全球视网膜疾病治疗市场在预测期内将以惊人的速度增长。人口老龄化是推动视网膜疾病治疗市场的另一个因素。随着人们年龄的增长，患 AMD 和糖尿病视网膜病变等视网膜疾病的风险也会增加。根据国家眼科研究所的数据，AMD 的患病率从 50-59 岁人群的 2% 增加到 75 岁及以上人群的 30%。随着全球人口老龄化，这一趋势预计将持续下去，从而支持未来几年全球视网膜疾病治疗市场的增长。

视网膜疾病的患病率不断上升

视网膜疾病是一组影响视网膜（眼睛后部的感光组织）的疾病。这些疾病会导致一系列症状，从轻度视力障碍到完全失明，是全世界视力障碍的主要原因。据世界卫生组织称，全球估计有 2.53 亿人患有视力障碍，其中 3600 万人失明。视网膜疾病是造成这些数字的一个重要原因，其中年龄相关性黄斑变性、糖尿病性视网膜病变和视网膜脱离等疾病是视力障碍和失明的最常见原因。

年龄相关性黄斑变性 (AMD) 是一种主要影响老年人的视网膜进行性变性，是发达国家视力障碍的主要原因。据美国眼科学会称，美国估计有 1100 万人患有某种形式的 AMD，随着人口老龄化，这一数字预计还会增加。糖尿病视网膜病变是糖尿病的一种并发症，可导致视网膜进行性损伤，是全世界视力障碍和失明的另一个常见原因。据国际糖尿病联盟称，全球估计有4.63 亿人患有糖尿病，预计到2045 年这一数字将增至7 亿。其中，多达三分之一的人面临患糖尿病视网膜病变的风险，估计三分之一的人面临患糖尿病视网膜病变的风险。糖尿病患者已经出现某种形式的视力丧失。其他视网膜疾病，例如视网膜脱离和色素性视网膜炎，虽然不太常见，但仍然会对人的视力和生活质量产生重大影响。视网膜脱离（视网膜与下方组织的分离）大约影响每10,000 人中就有一个，而色素性视网膜炎（一种导致进行性视力丧失的遗传性疾病）估计每3,000 至4,000 人中就有一个受到影响。人群中视网膜疾病患病率的增加将导致治疗需求的增加，从而推动全球视网膜疾病治疗市场的增长。

医疗保健技术的进步

医疗保健技术的进步正在推动全球视网膜疾病治疗市场。新的疗法和技术不断涌现，为视网膜疾病患者提供了更好的治疗效果。例如，抗血管内皮生长因子（抗 VEGF）疗法彻底改变了 AMD 的治疗方法，有助于减缓疾病的进展并改善视力。此外，视网膜植入物和辅助设备为严重视力丧失的患者提供了新的选择，从而支持了全球视网膜疾病治疗市场的增长。

此外，虚拟现实（VR）和增强现实（AR）等辅助技术正在开发中，以帮助患有视网膜疾病的患者。这些技术可以模拟视觉环境并提供反馈以帮助患者驾驭周围环境。例如，VR耳机可以模拟繁忙的街道，让患者练习安全过马路。反过来，预计这将为未来几年全球视网膜疾病治疗市场的增长创造利润丰厚的机会。

政府支持倡议

视网膜疾病是全世界视力障碍和失明的主要原因，影响所有年龄段和人口统计的人群。虽然有几种有效的视网膜疾病治疗方法，但不同国家和地区获得这些治疗方法的情况差异很大。在美国、加拿大和西欧大部分地区等发达国家，视网膜疾病的治疗通常已经很成熟并且得到广泛应用。然而，在发展中国家，获得视网膜疾病治疗的机会往往因缺乏资源、基础设施和训练有素的医疗保健专业人员而受到限制。这些国家的许多视网膜疾病患者无法获得所需的护理，导致视力丧失和失明的发生率更高。

为了解决这种差距，已经建立了一些组织和政府倡议来改善发展中国家获得视网膜疾病治疗的机会。其中一项倡议是世界卫生组织的“2020 年愿景”计划，该计划旨在到2020 年消除可避免的失明。该计划的重点是改善发展中国家获得眼保健服务的机会，包括与视网膜疾病相关的服务。同样，在中国，政府启动了一项全国性计划，以改善获得眼保健服务的机会，包括与视网膜疾病相关的服务。该计划包括在全国建立300多家专业眼科医院，以及培训数千名眼科医生和其他眼保健专业人员。此外，在印度，政府制定了多项国家计划，为服务不足的人群提供免费或低成本的眼保健服务。这些计划包括流动眼科诊所、远程医疗服务以及白内障手术和其他眼科手术的补贴。此外，美国国家眼科研究所资助视网膜疾病研究，并为患者和医疗保健专业人员提供资源。不同组织和政府采取的此类倡议将增加人们获得有效视网膜治疗的机会，从而推动全球视网膜疾病治疗市场的增长。

最近的发展

• 2017年，美国食品和药物管理局批准了第一个针对一种名为莱伯先天性黑蒙的遗传性视网膜疾病的基因疗法。这种名为 Luxturna 的疗法使用病毒将缺陷基因的健康副本传递到视网膜，从而可以改善患有该疾病的人的视力。从那时起，其他几种治疗视网膜疾病的基因疗法已经在临床试验中进行了测试，并取得了有希望的结果。
• 2019年，加州大学洛杉矶分校的研究团队宣布，他们已成功利用干细胞恢復视网膜退化小鼠的视力。研究人员希望在不久的将来开始人体临床试验。
• 2019年，美国食品和药物管理局批准了一种名为Beovu的新药，用于治疗湿性年龄相关性黄斑变性，这是一种常见的视网膜疾病，可导致视力丧失。 Beovu 的工作原理是针对一种名为 VEGF 的蛋白质，这种蛋白质会导致视网膜中血管异常生长。该药物已被证明可以有效减少湿性年龄相关性黄斑变性患者的疾病进展并改善视力。

可用的定制：

根据给定的市场数据，TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项：

公司信息

• 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场细分

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要行业合作伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量和验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球视网膜疾病治疗市场展望

• 市场规模及预测
  • 按价值
• 市场份额及预测
  • 按类型（黄斑变性、糖尿病视网膜病变、其他）
  • 按剂型（凝胶、眼液、胶囊和片剂、滴眼剂、其他）
  • 按分销渠道（医院药房、网上药房、零售药房）
  • 按地区
  • 按公司划分 (2022)
• 产品图
  • 按类型
  • 按剂型分类
  • 按分销渠道
  • 按地区

第 6 章：北美视网膜疾病治疗市场展望

• 市场规模及预测
  • 按价值
• 市场份额及预测
  • 按类型
  • 按剂型分类
  • 按分销渠道
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲视网膜疾病治疗市场展望

• 市场规模及预测
  • 按价值
• 市场份额及预测
  • 按类型
  • 按剂型分类
  • 按分销渠道
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第 8 章：亚太地区视网膜疾病治疗市场展望

• 市场规模及预测
  • 按价值
• 市场份额及预测
  • 按类型
  • 按剂型分类
  • 按分销渠道
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳大利亚

第 9 章：南美洲视网膜疾病治疗市场展望

• 市场规模及预测
  • 按价值
• 市场份额及预测
  • 按类型
  • 按剂型分类
  • 按分销渠道
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲视网膜疾病治疗市场展望

• 市场规模及预测
  • 按价值
• 市场份额及预测
  • 按类型
  • 按剂型分类
  • 按分销渠道
  • 按国家/地区
• MEA：国家分析
  • 南非视网膜疾病治疗
  • 沙特阿拉伯视网膜疾病治疗
  • 阿联酋视网膜疾病治疗

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 类型发布

第 13 章：全球视网膜疾病治疗市场：SWOT 分析

第 14 章：波特的五力分析

• 行业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代类型的威胁

第15章：竞争格局

• 商业概览
• 产品类型
• 最近的发展
• 主要人员
• SWOT分析
  • Santen Pharmaceutical Co. Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Graybug Vision, Inc.
  • Shire (Takeda Pharmaceutical Company Limited)
  • Bayer AG
  • Genentech, Inc.
  • Acucela Inc.
  • Pfizer, Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Allergan plc. (AbbVie Inc.)

第 16 章：战略建议

Global Retinal Disorder Treatment Market is expected to grow at an impressive rate during the forecast period on account of the increasing prevalence of retinal disorders, the aging population, advancements in healthcare technology, and rising healthcare expenditure, among others. The aging population is another factor driving the retinal disorder treatment market. As people age, their risk of developing retinal disorders such as AMD and diabetic retinopathy increases. According to the National Eye Institute, the prevalence of AMD increases from 2% in people aged 50-59 years to 30% in people aged 75 years and older. This trend is expected to continue as the global population ages, thereby supporting the growth of global retinal disorder treatment market for the next few years.

Additionally, increasing research and development activities by various companies operating in the market and academic & research institutions across the globe for the identification and development of new treatments for retinal disorders or to improve the safety and efficacy of existing treatments is expected to create lucrative opportunities for the growth of global retinal disorder treatment market during the forecast period. According to clinicaltrials.gov, as of March 2023, there are around 1,198 studies in different phases of development related to retinal disorders treatment across the globe.

Rising healthcare expenditure is another factor driving the global retinal disorder treatment market. As healthcare expenditure increases, more resources are being dedicated to the development and commercialization of new therapies and technologies for retinal disorders. According to the National Health Expenditure Account, total healthcare expenditure in the United States reached USD 3.8 trillion in 2019.

Growing Prevalence of Retinal Disorders

Retinal disorders are a group of conditions that affect the retina, the light-sensitive tissue at the back of the eye. These conditions can cause a range of symptoms, from mild vision impairment to complete blindness, and are a leading cause of visual impairment worldwide. According to the World Health Organization, an estimated 253 million people worldwide live with visual impairment, of whom 36 million are blind. Retinal disorders are a significant contributor to these numbers, with conditions such as age-related macular degeneration, diabetic retinopathy, and retinal detachment among the most common causes of visual impairment and blindness.

Age-related macular degeneration (AMD), a progressive degeneration of the retina that affects mostly older adults, is a leading cause of visual impairment in developed countries. According to the American Academy of Ophthalmology, an estimated 11 million people in the United States have some form of AMD, with that number expected to increase as the population ages. Diabetic retinopathy, a complication of diabetes that can cause progressive damage to the retina, is another common cause of visual impairment and blindness worldwide. According to the International Diabetes Federation, an estimated 463 million people worldwide have diabetes, with that number expected to rise to 700 million by 2045. Of these, up to one-third are at risk of developing diabetic retinopathy, with an estimated one in three people with diabetes already experiencing some form of vision loss. Other retinal disorders, such as retinal detachment and retinitis pigmentosa, are less common but can still have a significant impact on a person's vision and quality of life. Retinal detachment, a separation of the retina from the underlying tissue, affects approximately one in every 10,000 people, while retinitis pigmentosa, a genetic disorder that causes progressive vision loss, affects an estimated one in every 3,000 to 4,000 people. The increasing prevalence of retinal disorders among the population will contribute to an increase in demand for treatments, thereby driving the growth of global retinal disorder treatment market.

Advancements in Healthcare Technology

Advancements in healthcare technology are driving the global retinal disorder treatment market. New therapies and technologies are emerging that offer improved outcomes for patients with retinal disorders. For example, anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of AMD, helping to slow the progression of the disease and improve vision. Additionally, retinal implants and assistive devices are providing new options for patients with severe vision loss, in turn supporting the growth of global retinal disorder treatment market.

Additionally, assistive technologies such as virtual reality (VR) and augmented reality (AR) are being developed to help patients with retinal disorders. These technologies can simulate visual environments and provide feedback to help patients navigate their surroundings. For example, a VR headset can simulate a busy street, allowing patients to practice crossing the road safely. This, in turn, is expected to create lucrative opportunities for the growth of global retinal disorders treatment market in the next few years.

Supportive Government Initiatives

Retinal disorders are a major cause of visual impairment and blindness worldwide, affecting people of all ages and demographics. While there are several effective treatments available for retinal disorders, access to these treatments varies widely across different countries and regions. In developed countries such as the United States, Canada, and much of Western Europe, retinal disorder treatment is generally well-established and widely available. In developing countries, however, access to retinal disorder treatment is often limited by a lack of resources, infrastructure, and trained healthcare professionals. Many people with retinal disorders in these countries are unable to receive the care they need, leading to a higher incidence of vision loss and blindness.

To address this disparity, several organizations and government initiatives have been established to improve access to retinal disorder treatment in developing countries. One such initiative was the World Health Organization's Vision 2020 program, which aimed to eliminate avoidable blindness by the year 2020. The program focused on improving access to eye care services in developing countries, including those related to retinal disorders. Similarly, in China, the government has launched a nationwide program to improve access to eye care services, including those related to retinal disorders. The program includes the establishment of more than 300 specialized eye hospitals across the country, as well as the training of thousands of ophthalmologists and other eye care professionals. Additionally, in India, the government has established several national programs to provide free or low-cost eye care services to underserved populations. These programs include mobile eye clinics, telemedicine services, and subsidies for cataract surgery and other eye surgeries. Also, the National Eye Institute in the US funds research on retinal disorders and provides resources for patients and healthcare professionals. Such initiatives taken by different organizations and governments will increase the access of people to effective retinal treatment, thereby driving the growth of global retinal disorder treatment market.

Market Segmentation

Global Retinal Disorder Treatment Market can be segmented by type, dosage form, distribution channel, and by region. Based on type, Global Retinal Disorder Treatment market can be categorized into macular degeneration, diabetic retinopathy, and others. By dosage form, the Global Retinal Disorder Treatment market can be segmented into gels, eye solutions, capsules & tablets, eye drops, and others. By distribution channel, the Global Retinal Disorder Treatment market can be fragmented into hospital pharmacies, online pharmacy, and retail pharmacies. Regionally, the global Retinal Disorder Treatment market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Santen Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Graybug Vision, Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech, Inc., Acucela Inc., Pfizer, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Allergan plc. (AbbVie Inc.), among others, are some of the leading players operating in the global Retinal Disorder Treatment market.

Recent Developments

• In 2017, the U.S. Food and Drug Administration approved the first gene therapy for an inherited retinal disorder called Leber congenital amaurosis. This therapy, called Luxturna, uses a virus to deliver a healthy copy of a defective gene to the retina, which can improve vision in people with the disorder. Since then, several other gene therapies for retinal disorders have been tested in clinical trials with promising results.
• In 2019, a team of researchers at the University of California, Los Angeles, announced that they had successfully used stem cells to restore vision in mice with retinal degeneration. The researchers hope to begin human clinical trials in the near future.
• In 2019, the U.S. Food and Drug Administration approved a new drug called Beovu for the treatment of wet age-related macular degeneration, a common retinal disorder that can lead to vision loss. Beovu works by targeting a protein called VEGF, which can cause abnormal blood vessel growth in the retina. The drug has been shown to be effective at reducing the progression of the disease and improving vision in people with wet age-related macular degeneration.

Report Scope:

In this report, Global Retinal Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Retinal Disorder Treatment Market, By Type:

• Macular Degeneration
• Diabetic Retinopathy
• Others

Retinal Disorder Treatment Market, By Dosage Form:

• Gels
• Eye Solution
• Capsules & Tablets
• Eye Drops
• Others

Retinal Disorder Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Retinal Disorder Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Retinal Disorder Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Retinal Disorder Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Macular Degeneration, Diabetic Retinopathy, Others)
  • 5.2.2. By Dosage Form (Gels, Eye Solution, Capsules & Tablets, Eye Drops, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Map
  • 5.3.1. By Type
  • 5.3.2. By Dosage Form
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Retinal Disorder Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Dosage Form
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Retinal Disorder Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Dosage Form
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Retinal Disorder Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Dosage Form
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Retinal Disorder Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Dosage Form
      • 6.3.3.2.3. By Distribution Channel

7. Europe Retinal Disorder Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Dosage Form
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Retinal Disorder Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Dosage Form
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Retinal Disorder Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Dosage Form
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Retinal Disorder Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Dosage Form
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Retinal Disorder Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Dosage Form
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Retinal Disorder Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Dosage Form
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Retinal Disorder Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Dosage Form
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Retinal Disorder Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Dosage Form
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Retinal Disorder Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Dosage Form
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Retinal Disorder Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Dosage Form
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Retinal Disorder Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Dosage Form
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Retinal Disorder Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Dosage Form
      • 8.3.5.2.3. By Distribution Channel

9. South America Retinal Disorder Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Dosage Form
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Retinal Disorder Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Dosage Form
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Retinal Disorder Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Dosage Form
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Retinal Disorder Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Dosage Form
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Retinal Disorder Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Dosage Form
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Retinal Disorder Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Dosage Form
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Retinal Disorder Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Dosage Form
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Retinal Disorder Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Dosage Form
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Type Launches

13. Global Retinal Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Types

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Type Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Santen Pharmaceutical Co. Ltd.
  • 15.5.2. Regeneron Pharmaceuticals Inc.
  • 15.5.3. Graybug Vision, Inc.
  • 15.5.4. Shire (Takeda Pharmaceutical Company Limited)
  • 15.5.5. Bayer AG
  • 15.5.6. Genentech, Inc.
  • 15.5.7. Acucela Inc.
  • 15.5.8. Pfizer, Inc.
  • 15.5.9. Kubota Pharmaceutical Holdings Co., Ltd.
  • 15.5.10. Allergan plc. (AbbVie Inc.)

16. Strategic Recommendations